Schering AG/Epix' Imaging Agent Requires Additional Clinical Studies, FDA Says

FDA requests further clinical studies for MS-325 (gadofosveset trisodium) to demonstrate efficacy, the "approvable" letter states. The outstanding questions relate to the non-contrast comparator scanning methods used in Phase III trials and the statistical treatment of uninterpretable baseline scans.